Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Advanced Gastric Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    275 result(s) found for: Advanced Gastric Cancer. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-001419-25 Sponsor Protocol Number: GastricCHIMERAtrial Start Date*: 2021-04-09
    Sponsor Name:Jagiellonian University Medical College
    Full Title: Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial
    Medical condition: Gastric Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007350 Carcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004996-24 Sponsor Protocol Number: ONCOL1 Start Date*: 2008-12-05
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: A RANDOMIZED PHASE II STUDY OF TAXOTERE, OXALIPLATIN, CAPECITABINE (TOX) OR EPIDOXORUBICIN, OXALIPLATIN AND CAPECITABINE (EOX) IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC C...
    Medical condition: PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004357-86 Sponsor Protocol Number: GOIRC-05-2019 Start Date*: 2020-07-17
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (G...
    Medical condition: HER2 positive advanced gastric or gastro-esophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022699-30 Sponsor Protocol Number: B-DOCT Start Date*: 2011-01-19
    Sponsor Name:Nederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis
    Full Title: Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Me...
    Medical condition: Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063916 Metastatic gastric cancer PT
    12.1 10017758 Gastric cancer LLT
    12.1 10066896 HER-2 positive gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002715-40 Sponsor Protocol Number: CRO-2008-26 Start Date*: 2008-11-02
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
    Full Title: NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY
    Medical condition: PATIENTS WITH OPERABLE GASTRIC ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061968 Gastric neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006544-20 Sponsor Protocol Number: CRAD001R2301 Start Date*: 2009-07-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer af...
    Medical condition: advanced gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004512-43 Sponsor Protocol Number: ML20777 Start Date*: 2007-01-29
    Sponsor Name:Roche Farma, S.A.
    Full Title: Estudio Fase II abierto de Capecitabina (Xeloda®) como fluoropirimidina de elección en combinación con quimioterapia en pacientes con cáncer gástrico Avanzado y/o Metastático susceptibles de ser tr...
    Medical condition: Capecitabine in combination with chemotherapy in patients with advanced and/or metastatic gastric cancer suitable to be treated with a fluoropirimidine based regimen to assess the safety profile sp...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003301-42 Sponsor Protocol Number: EMR100070-008 Start Date*: 2016-05-19
    Sponsor Name:Merck KGaA
    Full Title: A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma
    Medical condition: Unresectable, recurrent, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005046-37 Sponsor Protocol Number: COUGAR-02 Start Date*: 2007-12-28
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: COUGAR-02: A randomised phase III study of docetaxel vs active symptom control in patients with relapsed oesophago-gastric adenocarcinoma
    Medical condition: Advanced oesophago-gastric cancer which has previously been treated with a platinum and fluoropyrimidine based combination
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001173 Adenocarcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016468-35 Sponsor Protocol Number: D8480C00067 Start Date*: 2016-03-29
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in ...
    Medical condition: Gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017758 Gastric cancer LLT
    12.1 10017760 Gastric cancer NOS LLT
    12.1 10017766 Gastric cancer stage IV NOS LLT
    12.1 10017767 Gastric cancer stage IV with metastases LLT
    12.1 10017768 Gastric cancer stage IV without metastases LLT
    12.1 10061967 Gastric cancer stage IV LLT
    12.1 10063916 Metastatic gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007273-23 Sponsor Protocol Number: JBZ-CHI-BO-2007-12 Start Date*: 2008-02-08
    Sponsor Name:Jeroen Bosch Hospital
    Full Title: A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer
    Medical condition: Gastric carcinoma stadium Ib-IVa
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017770 Gastric carcinoma LLT
    9.1 10008452 Chemotherapy multiple agents systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003300-23 Sponsor Protocol Number: EMR100070-007 Start Date*: 2016-06-13
    Sponsor Name:Merck KGaA
    Full Title: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metas...
    Medical condition: Advanced (unresectable, locally advanced or metastatic) adenocarcinoma of the stomach, or of the gastro-esophageal junction (GEJ)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) RO (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001500-36 Sponsor Protocol Number: 27/2006/O/Sper Start Date*: 2006-05-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Radio-controlled surgery RGS in the gastric carcinoma locally advanced subordinate to neoadiuvante medical therapy. Clinical study of feasibilities and correlation with the traditional methodica...
    Medical condition: carcinoma of the locally advanced stomach
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017758 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005464-92 Sponsor Protocol Number: DOCOX-C-00082 Start Date*: 2006-06-07
    Sponsor Name:Sanofi-aventis groupe
    Full Title: Estudio randomizado de fase II de Docetaxel en combinación con Oxaliplatino con o sin 5-FU o Capecitabina, en cáncer gástrico metastásico o en recurrencia local que no haya sido tratado previamente...
    Medical condition: Cáncer gástrico metastásico o en recurrencia local que no haya sido tratado previamente para la enfermedad avanzada con quimioterapia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed) DE (Completed) HU (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003493-13 Sponsor Protocol Number: BGB-290-303 Start Date*: 2018-05-24
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based...
    Medical condition: Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000853-22 Sponsor Protocol Number: CA184-162 Start Date*: 2012-06-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally...
    Medical condition: Locally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007798-18 Sponsor Protocol Number: AIO/CAO-STO-0801 Start Date*: 2010-07-01
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Ga...
    Medical condition: Subjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001069-18 Sponsor Protocol Number: CA224-060 Start Date*: 2018-09-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NO (Completed) BE (Completed) PL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006198-25 Sponsor Protocol Number: HE7/12 Start Date*: 2012-10-24
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer
    Medical condition: Inoperable gastric and gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023377-19 Sponsor Protocol Number: D2610C00004 Start Date*: 2011-11-03
    Sponsor Name:AstraZeneca
    Full Title: A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Th...
    Medical condition: FGFR, Amplification, polysomy, gastro-oesophageal junction cancer, lower third oesophageal cancer, gastric cancer, randomised, efficacy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061967 Gastric cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030159 Oesophageal carcinoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017765 Gastric cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026104 Malignant neoplasm of lower third of esophagus LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 22 07:23:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA